​Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 21, Sarah James from Cantor Fitzgerald reiterated a Buy rating on Elevance Health, Inc. (NYSE:ELV) with a price target of $400. ​The firm maintains a cautious outlook on the 2026 Medicaid Environment, noting that the company has conservative elements in its 2026 earnings per share projections. In addition, the firm also believes that execution in Medicare Advantage, commercial business, and Carel ...

Elevance Health, Inc. (NYSE:ELV) is one of the best long term low volatility stocks to buy right now. Elevance Health, Inc. (NYSE:ELV) reported its fiscal Q3 2025 results on October 21, announcing $50.1 billion in operating revenue for the quarter, up 12.0% compared to the same quarter last year. Diluted EPS for the quarter reached $5.32, while adjusted diluted EPS was $6.03. Elevance Health (ELV) Drops 18.66% After Dismal Q2 Earnings The company reaffirmed its fiscal year 2025 benefit expense ratio and ...